Fentanyl pectin nasal spray: A novel intranasal delivery method for the treatment of breakthrough cancer pain

Expert Review of Clinical Pharmacology

Volumn 6, Issue 1, 2013, Pages 9-22

  Bulloch, Marilyn N ^a,b   Hutchison, Amber M ^b  

^a University Medical Center   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

breakthrough cancer pain; fentanyl; intranasal; pectin

Indexed keywords

CARBAMAZEPINE; CHITOSAN; CLARITHROMYCIN; DECONGESTIVE AGENT; DILTIAZEM; FENTANYL; FENTANYL CITRATE; ITRACONAZOLE; KETOCONAZOLE; MONOAMINE OXIDASE INHIBITOR; MORPHINE; NALTREXONE; OXYCODONE; PECTIN; PHENOBARBITAL; PHENYTOIN; PLACEBO; POLOXAMER; RIFAMPICIN; RITONAVIR;

ANALGESIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER PAIN; CANCER PATIENT; CHEMISTRY; CONSTIPATION; DEHYDRATION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EPISTAXIS; ERYTHEMA; HEADACHE; HUMAN; INFLAMMATION; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NONCARDIAC CHEST PAIN; NOSE IRRITATION; NOSE OBSTRUCTION; PATIENT SATISFACTION; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINORRHEA; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84871957963     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.69     Document Type: Article

References (32)

1. Leppert W. Role of intranasal fentanyl in breakthrough pain management in cancer patients. Cancer Manag. Res. 2, 225-232 (2010
2. Vissers DC, Lenre M, Tolley K, Jakobsson J, Sendersky V, Jansen JP. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer. Value Health 14(2), 274-281 (2011
3. Portenoy RK, Raffaeli W, Torres LM et al.; Fentanyl Nasal Spray Study 045 Investigators Group. Long-Term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-Tolerant patients. J. Opioid Manag. 6(5), 319-328 (2010
4. Davies A, Sitte T, Elsner F et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate release morphine sulfate in breakthrough cancer pain. J. Pain Sympt. Mgmt 41, 358-366 (2011
5. Taylor D, Galan V, Weinstein SM, Reyes E, Pupo-Araya AR, Rauck R; Fentanyl Pectin Nasal Spray 043 Study Group. Fentanyl pectin nasal spray in breakthrough cancer pain. J. Support. Oncol. 8(4), 184-190 (2010
6. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G; Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. The management of cancer-related breakthrough pain: Recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur. J. Pain 13(4), 331-338 (2009
7. Swarm R, Abernethy AP, Anghelescu DL et al.; NCCN Adult Cancer Pain. Adult cancer pain. J. Natl Compr. Canc. Netw. 8(9), 1046-1086 (2010
8. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol. Scand. 46(7), 759-770 (2002 (Pubitemid 34803193)
9. Grassin-Delyle S, Buenestado A, Naline E et al. Intranasal drug delivery: An efficient and non-Invasive route for systemic administration, focus on opioids. Pharmacol. Ther. 134, 366-379 (2012
10. Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs 72(2), 181-190 (2012
11. Elsner F, Zeppetella G, Porta-Sales J, Tagarro I. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-Tolerant cancer patients. Clin. Drug Investig. 31(9), 605-618 (2011
12. Subsys (fentanyl) Sublingual Spray. Prescribing Information. Insys Therapeutics, Inc, Phoenix, AZ, USA (2012
13. Lazanda (fentanyl) Nasal Spray. Prescribing Information. Archimedes Pharma US Inc., Bedminster, NJ, USA (2012
14. PecFent (fentanyl pectin nasal spray). Summary of Product Characteristics. Archimedes Development Ltd, Nottingham, UK (2012
15. Instanyl (intranasal fentanyl spray). Summary of Product Characteristics. Nycomed UK Ltd, Marlow, Buckinghamshire, UK (2011
16. Paech MJ, Bloor M, Schug SA. New formulations of fentanyl for acute pain management. Drugs Today 48(2), 119-132 (2012
17. Mystakidou K, Panagiotou I, Gouliamos A. Fentanyl nasal spray for the treatment of cancer pain. Expert Opin. Pharmacother. 12(10), 1653-1659 (2011
18. Fisher A, Watling M, Smith A, Knight A. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan, and chitosan-poloxamer 188. Int. J. Clin. Pharmacol. Ther. 48, 138-145 (2010
19. Fisher A, Watling M, Smith A, Knight A. Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100-800 μg in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 48, 860-867 (2010
20. Watts P, Smith A. PecSys: In situ gelling system for optimised nasal drug delivery. Expert Opin. Drug Deliv. 6(5), 543-552 (2009
21. Kaasa S, Moksnes K, Nolte T, Lefebvre-Kuntz D, Popper L, Kress HG. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J. Opioid Manag. 6(1), 17-26 (2010
22. Portenoy RK, Burton AW, Gabrail N, Taylor D; Fentanyl Pectin Nasal Spray 043 Study Group. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain. Pain 151(3), 617-624 (2010
23. Taylor D, Galan V, Weinstein SW et al. Fentanyl pectin nasal spray in breakthrough cancer pain. J. Support Oncol. 8, 184-190 (2010
24. Fallon M, Reale C, Davies A et al.; Fentanyl Nasal Spray Study 044 Investigators Group. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: A multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J. Support. Oncol. 9(6), 224-231 (2011
25. Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: A validation study. J. Pain Symptom Manage. 25(5), 406-411 (2003 (Pubitemid 36506668)
26. Bowie MW, Slattum PW. Pharmacodynamics in older adults: A review. Am. J. Geriatr. Pharmacother. 5(3), 263-303 (2007 (Pubitemid 350048507)
27. Davis G, Fisher A, Knight A, Love R. Nasalfent, a novel intranasal formulation of fentanyl, is rapidly effective and well-Tolerated during treatment of breakthrough cancer pain. Proceedings of 10th Congress of the European Association for Palliative Care. Budapest, Hungary (2007) (Oral abstract 25
28. Davis G, Fisher A, Knight A, Love R. Nasalfent, a novel intranasal formulation of fentanyl, is rapidly effective and well-Tolerated during treatment of breakthrough cancer pain. Proceedings of 10th Congress of the European Association for Palliative Care. Budapest, Hungary (2007 (Poster abstract 711
29. Davis G, Fisher A, Knight A, Love R. Rapid pain relief with fentanyl citrate nasal spray (Nasalfent) in cancer patients with breakthrough pain. Proceedings of 10th Congress of the European Association for Palliative Care. Budapest, Hungary (2007) (Poster abstract 712
30. Radbruch L, Torres LM, Ellershaw JE et al. Long-Term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain. Support. Care Cancer 20(3), 565-573 (2012
31. American Cancer Society. Global Cancer Facts & Figures. 2nd Edition. American Cancer Society, Atlanta, GA, USA (2011
32. AWMSG Secretariat Assessment Report - Advice no. 0911Fentanyl (PecFent). (2011